Pentraxin3 is a novel marker for stent-induced inflammation and neointimal thickening.
about
Plasma Pentraxin3 is a novel marker for nonalcoholic steatohepatitis (NASH).Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilationPentraxin 3 as a novel marker predicting congestive heart failure in subjects with acute coronary syndromeMorning pentraxin3 levels reflect obstructive sleep apnea-related acute inflammationInfluence of pentraxin 3 (PTX3) genetic variants on myocardial infarction risk and PTX3 plasma levels.A RTK-based functional RNAi screen reveals determinants of PTX-3 expression.Prognostic value of plasma pentraxin-3 levels in patients with stable coronary artery disease after drug-eluting stent implantation.Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes.Dexamethasone prophylaxis in pediatric open heart surgery is associated with increased blood long pentraxin PTX3: potential clinical implications.High pentraxin 3 level predicts septic shock and bacteremia at the onset of febrile neutropenia after intensive chemotherapy of hematologic patientsAssociations between pentraxin 3 and severity of coronary artery disease.Pentraxin 3(PTX 3): an endogenous modulator of the inflammatory responseBiochemical analysis of pentraxin 3 and fibrinogen levels in experimental periodontitis model.Long pentraxin 3: experimental and clinical relevance in cardiovascular diseasesIncreased long-term expression of pentraxin 3 in irradiated human arteries and veins compared to internal controls from free tissue transfersTranslational mini-review series on immunology of vascular disease: mechanisms of vascular inflammation and remodelling in systemic vasculitis.The long pentraxin PTX3 at the crossroads between innate immunity and tissue remodelling.The long pentraxin PTX3: a paradigm for humoral pattern recognition molecules.Long-term prognostic utility of pentraxin 3 and D-dimer as compared to high-sensitivity C-reactive protein and B-type natriuretic peptide in suspected acute coronary syndrome.Pentraxin 3 predicts complicated course of febrile neutropenia in haematological patients, but the decision level depends on the underlying malignancy.Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation.Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations.Cardiac rehabilitation decreases plasma pentraxin 3 in patients with cardiovascular diseases.Implications of pentraxin 3 levels in patients with acute aortic dissection.Cerebrospinal fluid pentraxin 3 early after subarachnoid hemorrhage is associated with vasospasm.Selective up-regulation of the soluble pattern-recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: Relevance for recent optic nerve ischemia
P2860
Q33384921-CCBAAB5E-961D-4195-93A7-2E4B35F28612Q33944773-5AE91D9A-30FA-4639-B5A0-089D442B892AQ34104578-09741ECF-31BD-4B28-BB7D-543C99F50D2AQ34519002-634EF48A-AC8D-42F4-A41D-352A4B9DE420Q34534979-E199AB75-FAE3-4CE8-A7FF-34278C6F14DDQ34662196-CB6AD515-FA6F-4DA5-AAA0-B0AE169D7D1FQ34694726-30BC6DA8-58C4-403A-9E37-0305922DA7B6Q34751855-8CFE4532-D77C-4050-BECB-68FADDDDF867Q35110197-CC0B715C-362D-494C-AB3A-50132845C286Q35193767-0C658C9B-C7F1-4A3D-9886-A2D013858A58Q35332533-31D8C658-35EE-49D5-A519-6A3D7670D4D0Q35915482-B00AF7B8-D59F-44C0-A292-9ECC9864E530Q36200128-93E8AF7E-A6DC-47EC-B61E-EF86E85B9A52Q36830914-268DACC3-58AC-4CEC-8BF3-B8DED23D8D9BQ37361154-420EB139-14F4-4824-9BAA-779216519356Q37421806-5D1BE17F-886B-4C5A-95D9-79C602461170Q37851153-1721157C-F478-4324-8890-F2C2AE9EB021Q38092832-16A33D34-7B29-491B-85F4-9B1EC5309480Q38935475-7165875C-07D0-4DE0-AED5-CDA0DFEBA8A8Q40321630-9949D8D1-F408-487E-8D15-1DA79FABD7EFQ46001389-5A8EE5CD-B114-4479-90A5-271195004BB3Q46071688-4C6183A2-29FB-49AE-90DE-0EFF7278AA49Q48901808-C9FDCC10-7C0F-435C-A733-8E691753A40CQ53081569-3802A278-950A-4F43-B47C-E9C749AA650AQ53985364-3F617DC6-56DF-4661-BBB8-802CB1F5A83CQ56942323-DBA87CCD-503A-42E5-8E29-4B81531299ED
P2860
Pentraxin3 is a novel marker for stent-induced inflammation and neointimal thickening.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Pentraxin3 is a novel marker for stent-induced inflammation and neointimal thickening.
@en
Pentraxin3 is a novel marker for stent-induced inflammation and neointimal thickening.
@nl
type
label
Pentraxin3 is a novel marker for stent-induced inflammation and neointimal thickening.
@en
Pentraxin3 is a novel marker for stent-induced inflammation and neointimal thickening.
@nl
prefLabel
Pentraxin3 is a novel marker for stent-induced inflammation and neointimal thickening.
@en
Pentraxin3 is a novel marker for stent-induced inflammation and neointimal thickening.
@nl
P2093
P1433
P1476
Pentraxin3 is a novel marker for stent-induced inflammation and neointimal thickening.
@en
P2093
Akira Sugiyama
Daisuke Fujimatsu
Koichi Node
Norihiko Kotooka
Shigemsa Hashimoto
Teruo Inoue
Toshifumi Morooka
Toshihiko Uchida
Yutaka Hikichi
P304
P356
10.1016/J.ATHEROSCLEROSIS.2007.05.031
P577
2007-07-19T00:00:00Z